LACK OF INFUSION-RELATED ADVERSE EVENTS WITH ANIDULAFUNGIN (ANID)

Schranz J, Krause D, Henkel T

Author address: 

NULL

Abstract: 

Background: ANID is a novel semisynthetic echinocandin in late-stage development. ANID has potent in vitro and in vivo fungicidal activity against medically significant fungi, including Candida and Aspergillus spp. Certain members of the echinocandin class are associated with possible histamine-mediated symptoms including isolated reports of rash, facial swelling, pruritus, sensation of warmth or bronchospasm. In Phase 2 studies, ANID infusion associated adverse events rarely occurred at rates
2003

abstract No: 

NULL

Full conference title: 

The 15 th Congress of the International Society for Human and Animal Mycology
    • ISHAM 15th (2003)